PR Teaser: WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. Read the full press release »

WALTHAM, Mass.--(BUSINESS WIRE)--May 12, 2021-- PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.

The latest news from Nexcelom Bioscience March 20, 2018 - Nexcelom Bioscience announces strategic growth investment from Ampersand Capital Partners (PDF) March 20, 2018, Lawrence, MA -- Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners.  The funding will be primarily used to support Nexcelom’s worldwide growth initiatives. Founded in 2003, Nexcelom is a fast-growing supplier of innovative cellular analysis instruments, software and related consumables used in a broad range of research fields including immuno-oncology, cell therapy, drug discovery, [...]